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Atrial fibrillation is an important comorbidity with substantial
therapeutic implications in dialysis patients but its
prevalence varies in different studies. We used a database
that includes patients in the United States on hemodialysis
who were eligible for government assistance with
prescription drugs. We then used ICD-9 codes from billing
claims in this database to identify patients with chronic atrial
fibrillation. Multivariable logistic regression was used to
determine adjusted prevalence odds ratios for associated
factors. Of 63,884 individuals, the prevalence of chronic atrial
fibrillation was 7%. The factors of age over 60 years, male,
Caucasian, body mass index over 25kg/m2, coronary artery
disease, and heart failure were all significantly associated
with chronic atrial fibrillation. Prevalence rates, particularly in
younger patients, were far higher than those reported in an
age group–matched nondialysis population. Thus, given its
clinical impact, future efforts are needed to examine risk
factors for adverse outcomes in chronic atrial fibrillation, and
to identify appropriate management strategies for this
disorder, as well as opportunities for quality improvement
in this vulnerable population.
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Atrial fibrillation (AF) is common in end-stage renal disease
(ESRD) patients on maintenance dialysis,1–9 is independently
associated with mortality in both general10 and dialysis8,11
populations, and has important therapeutic implications.
A full understanding of chronic AF prevalence, factors
associated with its prevalence, and the outcomes of ESRD
patients with chronic AF could be used to inform practi-
tioners about the patterns of current health-care delivery and
opportunities for improvement. Although recent studies
examining the epidemiology of chronic AF in cohorts drawn
from a large dialysis-provider organization,12 from the
Dialysis Outcomes and Practice Patterns Study (DOPPS),8
and in United States Renal Data System (USRDS) data13
signal renewed interest in this area, estimates of chronic AF
prevalence remain quite variable, ranging from 6%1 to nearly
27.0%.7,8 The wide variability of these estimates stems, in
part, from differences in individual study samples, study
design (for example, prospective cohort vs. retrospective
cohort vs. cross-sectional studies), classification of AF (for
example, chronic vs. transient or perioperative), and
diagnostic strategies (for example, self-reports vs. targeted
identification in longitudinal cohorts vs. retrospective records
review). Given this variability in the prevalence estimates for
chronic AF, additional work to rigorously characterize the
prevalence of this disorder and its associated factors is needed
to inform health-care decision making, especially in vulner-
able populations, such as those receiving government
financial assistance.
To study patients with chronic AF, we constructed a novel
database. This database links US Medicare data, which
contain federal billing claims for inpatient and outpatient
medical services permitting inferences about medical condi-
tions, with Medicaid data for state-supported individuals,
which contain prescription drug records. We then used an
algorithm, originally developed for identifying chronic AF in
the general population,14,15 to determine the prevalence of
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this disorder in dialysis patients. We elected to study patients
with both Medicare and Medicaid (‘dually-eligibles’) because
they represent a particularly vulnerable and resource-
intensive subgroup of patients, and they have readily available
prescription medication records (a required component
of our identification algorithm) by virtue of their Medi-
caid eligibility (http://www.npcnow.org/Public/Research___
Publications/Publications/pub_rel_research/pub_medicaid/
Pharmaceutical_Benefits_Under_State_Medical_Assistance_
Programs_2003.aspx). Our aims were to provide a compre-
hensive examination of the prevalence of, and factors asso-
ciated with, chronic AF, an important disorder with major
clinical implications.
RESULTS
A total of 430,227 individuals were receiving chronic dialysis
in 2004 and 2005. Figure 1 demonstrates the number of
individuals retained at each step of cohort construction.
A total of 125,668 individuals were dually eligible for at least
90 days. A small number of individuals (n¼ 462) were exclud-
ed because of hyperthyroidism, whereas a larger number of
them (n¼ 8384) were eliminated because of valvular heart
disease, leaving 116,858 individuals. Elimination of indivi-
duals with incomplete data left 102,748 individuals; the vast
majority of attrition occurred because information on body
mass index (BMI) and/or hemoglobin level was missing. A
total of 63,884 individuals were alive on 31 December 2005,
of whom 4488 satisfied the definition of chronic AF (7.0%).
Mean age of the overall cohort was 60.0±15.1 years.
Women comprised 53.0%, of whom 31.4% were Caucasian,
and 45.8% were African American. Well over half (60.8%) of
the patients with chronic AF had diabetes. Bivariate analyses
of the differences in characteristics between patients with and
without chronic AF are shown in Table 1. As noted, 7.0%
(95% confidence interval (CI) 6.8–7.2%) had chronic AF.
Patients with chronic AF were significantly (Po0.01) more
likely to be older (70.0 vs. 59.3 years), female, Caucasian,
have higher BMI values, be nonsmokers, be unemployed, be
unable to ambulate and transfer, and have diabetes mellitus,
congestive heart failure, coronary artery disease (CAD),
peripheral vascular disease, and a history of a cerebrovascular
accident; hypertension (HTN) was less common in patients
with chronic AF. Patients with the disorder were also more
likely to be on in-center hemodialysis and to have a
hemoglobin level of o11.0 g/dl.
Table 2 illustrates the result of multivariable modeling.
Age 460 years, male sex, Caucasian race, BMI X25 kg/m2,
lack of smoking, inability to ambulate, histories of CAD
congestive heart failure, and HTN as the cause of ESRD,
compared with those with diabetes mellitus as a cause of
ESRD and HTN as a comorbidity, were significantly
(Po0.01) associated with chronic AF. HTN was inversely
associated with chronic AF; specifically, the adjusted
prevalence odds ratio (APOR) of 0.79 indicates that, among
those individuals in whom HTN was not the primary cause
of ESRD, there was a lesser prevalence of chronic AF relative
to those who did not have HTN as a comorbidity on the CMS
2728 form. The use of self-care dialysis demonstrated
borderline significance (P¼ 0.011), whereas diabetes and a
hemoglobin level of o11 g/dl were not associated with
chronic AF. No lack of fit was detected for this model
(P40.05).
Dually eligible for Medicare and Medicaid (without any form of managed care) for  90 days:
N = 125,668
Excluded* because of hyperthyroidism (ICD-9, CPT, HCPCS, Medicaid prescriptions): N = 462
Excluded* because of valvular heart disease: N = 8384  
N =116,858 remaining
Excluded because of incomplete data: N = 14,110
N =  102,748 remaining
Excluded because of death or loss of dual eligibility before 31 December 2005: N = 38,864
N = 63,884 (‘denominator’)
Number satisfying definition of chronic atrial fibrillation:
N = 4488 (‘numerator’)
Figure 1 | Exclusion flowchart demonstrating the creation of the study cohort. *Some individuals were excluded because of both
hyperthyroidism and valvular heart disease. CPT, Common Procedural Terminology; HCPCS, Healthcare Common Procedural Coding System;
ICD-9, International Classification of Diseases–Ninth Revision.
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To facilitate comparison with data in the general popu-
lation, we calculated raw percentages of chronic AF by
age, stratified by decade and sex. Table 3 displays these
percentages. As expected, our rates were consistently higher
than those of the general population across age strata.15
Absolute rates were roughly twofold higher in the oldest
individuals (475 years) but410-fold in younger individuals
(age o55 years). In young individuals aged 40–44.9 years
(not specifically shown in Table 3), 1.4% of women and 2.2%
of men had chronic AF, whereas approximately one in six
individuals of 485 years had it. These findings demonstrate
that chronic AF both occurs at a younger age in the dialysis
patients and has sustained high prevalence rates in the
elderly.
To determine the robustness of our findings, we per-
formed several sensitivity analyses. Using both the more
liberal (X2 claims, without consideration of an episode-
of-care window) and the more conservative (X3 or claims
without consideration of the episode-of-care window)
approaches, the estimated percentage of individuals with
chronic AF was 8.0% (95% CI 7.8–8.2%) and 5.5% (95% CI
5.3–5.7%), respectively. Logistic regression modeling to
determine APORs for covariates using the conservative
approach produced results very similar to those of our
primary analysis, with the only difference being that smoking
and inability to ambulate were no longer significant,
although the magnitude of the effects were nearly identical;
also, male sex became marginally insignificant (P¼ 0.018),
although its magnitude of the APOR (1.09) was nearly
identical to that obtained earlier (1.12).
To determine whether our analysis in dually eligible
patients could be extrapolated to the larger body of chronic
dialysis patients, we ran a comparable series of analyses, using
the primary approach of X2 claims plus the episode-of-care
window restriction, in the entire group of Medicare dialysis
patients (that is, irrespective of Medicaid eligibility). In this
cohort of 173,606 individuals, the overall raw percentage of
individuals with chronic AF was higher, at 9.6%, compared
with the 7.0% of the comparable approach in dually eligible
patients. However, mean age of the patients in this group was
Table 1 | Characteristics of dialysis patients with and without chronic AF
Characteristic Total (n=63,884) AF (n=4488) Non-AF (n=59,396) P-value
Age, years 60.0±15.1 70.0±11.8 59.3±15.0 o0.0001
Female sex, n (%) 33,827 (53.0) 2519 (56.1) 31,308 (52.7) o0.0001
Race/ethnicity, n (%) o0.0001
African American 29,229 (45.8) 1445 (32.2) 27,784 (46.8)
Caucasian 20,027 (31.4) 2191 (48.8) 17,836 (30.0)
Hispanic 10,532 (16.5) 551 (12.3) 9981 (16.8)
Other 4096 (6.4) 301 (6.7) 3795 (6.4)
BMI category, n (%) o0.0001
o20 kg/m2 5618 (8.8) 338 (7.5) 5280 (8.9)
20–24.9 kg/m2 17,988 (28.2) 1079 (24.0) 16,909 (28.5)
25–29.9 kg/m2 17,310 (27.1) 1238 (27.6) 16,072 (27.1)
430 kg/m2 22,968 (36.0) 1833 (40.8) 21,135 (35.6)
Smoker, n (%) 4264 (6.7) 213 (4.8) 4051 (6.8) o0.0001
Substance abuser, n (%) 2193 (3.4) 75 (1.7) 2118 (3.6) o0.0001
Unemployed, n (%) 59,861 (93.7) 4333 (96.6) 55,528 (93.5) o0.0001
Inability to ambulate, n (%) 2388 (3.7) 305 (6.8) 2083 (3.5) o0.0001
Inability to transfer, n (%) 806 (1.3) 117 (2.6) 689 (1.2) o0.0001
Primary cause of ESRD, n (%) o0.0001
Diabetes 31,230 (48.9) 2239 (49.9) 28,991 (48.8)
Hypertension 17,480 (27.4) 1252 (27.9) 16,228 (27.3)
Glomerulonephritis 6315 (9.9) 316 (7.0) 5999 (10.1)
Other 8859 (13.9) 681 (15.2) 8178 (13.8)
Comorbidities, n (%)
Hypertension 54,886 (85.9) 3797 (84.6) 51,089 (86.0) 0.009
Diabetes 37,001 (57.9) 2728 (60.8) 34,273 (57.7) o0.0001
CHF 17,619 (27.6) 1926 (42.9) 15,693 (26.4) o0.0001
CAD 11,863 (18.6) 1400 (31.2) 10,463 (17.6) o0.0001
PVD 6996 (11.0) 733 (16.3) 6263 (10.5) o0.0001
CVA 5257 (8.2) 518 (11.5) 4739 (8.0) o0.0001
Self-care dialysis, n (%) 3401 (5.3) 171 (3.8) 3230 (5.4) o0.0001
Hb o11.0 g/dl, n (%) 48,997 (76.7) 3342 (74.5) 45,655 (76.9) 0.0002
Abbreviations: AF, chronic atrial fibrillation; BMI, body mass index; CAD, coronary artery disease; CHF, congestive heart failure; CVA, cerebrovascular accident; ESRD, end-stage
renal disease; Hb, hemoglobin; PVD, peripheral arterial disease.
The P-values were from Pearson’s w2 test for categorical measures and the two-sample t-test for continuous measures.
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substantially higher than that in the dually eligible group
(63.6 vs. 59.4 years, respectively). Modeling in this group,
shown in Supplementary Table S1 online, yielded generally
similar results as before; all previously identified associations
remained intact, but the use of in-center hemodialysis now
became highly statistically significant, as did employment.
The APORs for most factors, however, were very similar to
those for the dually eligible patients (differing only at the
hundredths place), likely indicating the effect of the increased
power of the far larger Medicare cohort. Lack of HTN, as a
comorbidity, was once again associated with chronic AF.
DISCUSSION
In this study, we adapted a validated billing claims-based
algorithm for the identification of patients with chronic AF
in dialysis patients who are dually eligible for both Medicare
and Medicaid. We found that 7.0% of these individuals had
chronic AF. Our study compliments and expands upon
previous reports in several ways. First, we provide a precise
estimate of chronic AF prevalence in the dually eligible
dialysis population. Compared with other types of patients,
those with Medicare and Medicaid are disproportionately
likely to be women, African American, smokers, substance
abusers, and have functional physical limitations,16 and are
associated with disproportionate health-care costs, making
them a particularly important vulnerable group of patients to
study. Second, we demonstrate an approach through which
claims data can be used for identification of chronic AF in
dialysis patients. Finally, our large sample size permits fairly
precise quantification of the associations between chronic AF
prevalence and a variety of demographic, anthropometric,
risk behavior, functional status, comorbidity, dialysis mod-
ality, and laboratory-value factors as recorded upon dialysis
initiation, providing direction for future study.
A validated Medicare claims-based algorithm for identify-
ing chronic AF has been published in several widely
disseminated reports.14,15,17 We amended this approach
because manual inspection of the claim patterns in several
hundred patient records made it likely that many ‘outpatient’
AF claims were likely to be associated with a proximate
AF-related hospital admission and were therefore potentially
transient. Our episode-of-care window paradigm can mini-
mize misclassification of acute AF as being chronic and
improve the accuracy of future efforts to assess and improve
the quality of AF treatment in ESRD patients. The robustness
of our findings is supported by several sensitivity analyses,
using more liberal and conservative approaches, which had
minimal impact on our prevalence estimates. Importantly,
regardless of the approach used or the sample studied,
modeling of the associations between covariates and chronic
AF led to consistent APORs.
Table 2 | APOR estimates for dually eligible (Medicare and
Medicaid) dialysis patients with chronic atrial fibrillation
Characteristic APOR 95% CIs P-value
Age 460 years 3.54 3.27–3.84 o0.0001
Male sex 1.12 1.05–1.20 0.0005
Race/ethnicity
Caucasian — — —
African American 0.51 0.47–0.55 o0.0001
Hispanic 0.51 0.46–0.56 o0.0001
Other 0.71 0.62–0.81 o0.0001
BMI category
o20 kg/m2 1.01 0.89–1.15 0.87
20–24.9 kg/m2 — — —
25–29.9 kg/m2 1.20 1.10–1.31 o0.0001
430 kg/m2 1.47 1.35–1.59 o0.0001
Smoker 0.80 0.69–0.93 0.003
Substance abuser 0.83 0.65–1.06 0.13
Employed 0.87 0.74–1.03 0.12
Inability to ambulate 1.28 1.10–1.50 0.002
Inability to transfer 1.16 0.91–1.48 0.25
Comorbidities
Hypertensiona 0.79 0.72–0.87 o0.0001
Diabetesa 0.90 0.80–1.00 0.051
CAD 1.29 1.20–1.39 o0.0001
CHF 1.56 1.45–1.67 o0.0001
CVA 1.11 1.00–1.22 0.055
PVD 1.05 0.96–1.15 0.29
Cause of ESRD
HTN vs. DMb 1.26 1.13–1.41 o0.0001
HTN vs. GNc 1.11 0.98–1.270 0.12
HTN vs. Otherc 1.10 0.99–1.22 0.089
DM vs. GNd 0.88 0.76–1.03 0.13
DM vs. Otherd 0.87 0.77–0.99 0.031
Other vs. GNe 1.02 0.88–1.17 0.82
Self-care dialysis 0.81 0.69–0.95 0.011
Hb o11.0 g/dl 0.98 0.92–1.06 0.67
Abbreviations: APOR, adjusted prevalence odds ratio; BMI, body mass index;
CAD, coronary artery disease; CHF, congestive heart failure; CI, confidence interval;
CVA, cerebrovascular accident; DM, diabetes mellitus; ESRD, end-stage renal disease;
GN, glomerulonephritis; Hb, hemoglobin; HTN, hypertension; PVD, peripheral
arterial disease.
aAs patients were classified as having HTN, for analytic purposes, whether HTN was a
cause of ESRD or was listed as a comorbidity on the CMS 2728 form, the APOR
represents the association of HTN with chronic atrial fibrillation only in individuals
who did not have HTN as the cause of ESRD. The APOR for DM is conceptually
identical.
bAmong individuals with both HTN and DM as comorbidities.
cAmong individuals with HTN.
dAmong individuals with DM.
eAmong individuals irrespective of HTN or DM status.
Table 3 | Prevalence of chronic atrial fibrillation in dialysis
patients compared with an ambulatory patient population,
by age decade and sex
Females Males
Age, years
Dialysis
%
Ambulatory
%a
Dialysis
%
Ambulatory
%a
o55 1.9 (186/9967) 0.1 2.5 (339/13,528) 0.2
55 to 60 4.7 (181/3811) 0.4 5.4 (216/3990) 0.9
60 to 65 5.7 (214/3764) 1.0 7.1 (221/3094) 1.7
65 to 70 8.0 (358/4462) 1.7 9.2 (292/3190) 3.0
70 to 75 11.6 (500/4304) 3.4 12.2 (305/2508) 5.0
75 to 80 13.0 (463/3556) 5.0 14.8 (287/1935) 7.3
80 to 85 15.1 (373/2470) 7.2 16.6 (195/1178) 10.3
485 16.3 (244/1493) 9.1 18.0 (114/634) 11.1
aEstimates for ambulatory patients adapted from Go et al.15
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Our raw prevalence estimates appear to be somewhat
lower than some,6–8 but not all,12 previous reports. In terms
of raw percentages, the DOPPS investigators recently
reported a prevalence rate of 11.3–24.7% in Western
countries, with a US rate of 12.5%.8 However, our empiric
inspection of AF claims patterns in several hundred patients
suggested that some previously reported estimates may be
implausibly high. Recent work from a small, but in-depth,
study of 256 patients revealed that whereas 7.4% of patients
had permanent AF, 12.1% had any type of AF,11 suggest-
ing that a substantial proportion of individuals labeled as
having AF are likely to have transient AF or AF due to
secondary causes. Thus, high AF rates reported in other
studies may be because individuals with secondary causes
of AF or transient AF are being captured, and perhaps
misclassified, by their respective identification strategies.
Additional evidence for lower AF rates comes from a recent
report by Chan et al.,12 who concluded that AF rates were
‘only’ 4.5% in incident dialysis patients. It seems likely that
rates would become higher in dialysis populations consisting
of more ‘prevalent’ individuals, as increasing age, a con-
comitant growing comorbidity burden, and increased
exposure to the hemodialysis procedure itself (a physiological
‘stress test,’ particularly in the United States where rapid
ultrafiltration is commonplace) might be expected to result
in increased rates of chronic AF. A recent report by
Winkelmayer et al.13 found chronic AF rates in the general
Medicare dialysis population to be 10.7% in 2006. The rate
in their large and rigorous study may be somewhat higher
than that of ours because those investigators used a some-
what more liberal definition than did we to establish chronic
AF (for example, by requiring only 14 days between AF
claims).
Our large study enables more precise estimates of prevalence
and risk factors. As such, previously reported findings of
associations between various patient factors upon dialysis
initiation and chronic AF can be well quantified. As expected,
we echoed the finding of the association of age with AF
reported in the DOPPS database,8 the Dialysis Morbidity and
Mortality (DMMS) Wave II study,18 the recent USRDS study
by Winkelmayer et al.,13 and others.5,7,11 Caucasian race has
also been found to be associated with AF,8,13,18 as has
increasing BMI.8 Notably, the role of sex in dialysis patients
with AF as a whole remains unclear; although some investi-
gators report sex to be unassociated with either incident or
prevalent AF,5,7,8 and others report that female sex is the risk
factor,11 our finding of an association of male sex with chronic
AF is consistent with findings in the general population15 and
in another recent large study of dialysis patients.13 The
counterintuitive finding that smoking was inversely related to
chronic AF prevalence is probably because the patients with the
greatest comorbidity burden are generally counseled most
heavily to cease, at least in the setting of advanced chronic
kidney disease. As anticipated, CAD and congestive heart
failure emerged as important comorbidites associated with
chronic AF.8,11,13
One noteworthy finding was an inverse association, after
adjustment for other factors, between HTN and chronic AF
in our study. Among individuals without HTN as their
primary cause of ESRD, chronic AF was less common in
individuals with HTN as a comorbidity (defined as having
HTN designated as a CMS 2728 comorbidity) than in those
without. However, specific examination of individuals with
HTN as a CMS 2728 comorbidity demonstrated that, among
those with HTN as the cause of ESRD, the APORs for HTN as
the cause of ESRD compared with those with diabetes
mellitus as the cause of ESRD was significantly41.0 (APOR
E1.3); a similar, although nonsignificant, trend for both
glomerulonephritis and other causes of ESRD was observed
(both APORs E1.1). This overall finding is consistent with
clear demonstrations that long-standing HTN (such as that
severe enough to cause ESRD) is a risk factor for AF in the
general population.19–24 However, studies of prevalent
dialysis patients demonstrate that they may be characterized
by a distinct physiology, namely the controversially termed
phenomenon of ‘reverse epidemiology,’25,26 and this may
explain how HTN as a CMS 2728 comorbidity could be
associated with a decreased likelihood of chronic AF among
people who did not have HTN as their cause of renal failure
(that is, among people who apparently did not have HTN
severe enough to cause ESRD). Evidence from the DOPPS
database appears to support our results: although a formal
diagnosis of HTN was not associated with AF, low predialysis
systolic blood pressure was,8 lending plausibility to the
hypothesis that when patients with advanced kidney disease
or ESRD manifest AF, many of them are likely to be experi-
encing decreased cardiac output and concomitant hypo-
tension. As AF may contribute to hypotension in dialysis
patients, this might be an explanation for our findings.
Our study should be interpreted in the context of several
potential limitations. First, we did not have access to medical
charts and relied upon extensive administrative data. How-
ever, we adapted a well-established validated algorithm to
leverage these data to minimize the possibility that secondary,
transient, valvular, or postoperative causes of AF would be
misclassified as truly chronic AF. Second, we used the CMS
2728 form to identify comorbidities, as is widely done.27–33
Although this form has several strengths, a more rigorous,
but far more complex, approach would be to supplement
these diagnoses with a claims-based approach to identify
comorbidities. Such an approach exists,34,35 and should be
explored in future investigations. It would, however, require
a minimum survival of 9 months and would introduce
other biases into the analyses.36 Third, our primary analysis
was confined to dually eligible individuals. As individuals
with Medicaid are likely to be the most financially needy
and resource intense, and to have more comorbidities at
a younger age than the non-dually eligible population,16 our
results can only be generalized with much caution. For
example, in patient populations with fewer African-origin
individuals, the overall rates are likely to be higher. However,
we did perform an additional analysis in the general dialysis
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population with Medicare, and found consistent APORs for
the various covariates. Finally, given the retrospective nature
of this study with its point-prevalence approach, we cannot
infer causality; we cannot, for example, declare that a marker
of functional status (for example, inability to ambulate)
‘predicts’ the development of chronic AF. Rather, the purpose
of this study was to elucidate broad associations worthy of
future detailed study.
In conclusion, we used a billing claims-based approach to
determine the prevalence of chronic AF, an important
comorbidity with significant clinical implications, in a
vulnerable and resource-intense group of dialysis patients,
namely those dually eligible for Medicare and Medicaid. As
expected, the prevalence rate is far higher than that of the
nondialysis population, a finding that is particularly striking
in younger individuals. Male sex, Caucasian race, increasing
BMI, inability to ambulate, and the presence of CAD and
heart failure are also associated with the disorder. Further
investigation of the role these factors have in chronic AF
could provide an opportunity to provide better care in this
resource-intense group of dialysis patients, and in the dialysis
population as a whole.
MATERIALS AND METHODS
Study design
A retrospective cohort analysis of patients undergoing maintenance
dialysis during the 2-year period of 1 January 2004 to 31 December
2005 was used to identify people with chronic AF, as described
below. The intention was to study individuals with persistent or
recurrent (and therefore chronic) AF, rather than individuals with
transient (typically postoperative) AF or AF due to structural heart
disease. We identified chronic AF in patients who were observable
for at least 3 months during the 2-year window, after having initially
survived their first 90 days on dialysis, and who were alive with dual
eligibility on 31 December 2005 to estimate the point prevalence of
chronic AF.
Data sources for analysis
Our data were derived from two primary sources. The first was the
USRDS, a national data system that collects and analyzes data on
virtually all patients undergoing chronic dialysis in the United
States. The USRDS incorporates data on inpatient and outpatient
medical claims paid by Medicare, a federally funded health-care
program that pays health-care costs (excluding prescription drugs
until 2006) for the vast majority of dialysis patients. Medicare
claims, which are commonly used in secondary data analyses in the
United States,17,37–40 contain International Classification of Dis-
eases–Ninth Revision (ICD-9) codes keyed to specific dates of
service. As such, when a provider (such as a physician or hospital)
submits a billing claim to Medicare, the presence of a medical
condition in a specific patient at a specific time can be inferred.
The other source of data was Medicaid prescription drug billing
claims. Medicaid is a program in the United States that is designed
to assist the most financially needy individuals with health-care
costs, particularly prescription drugs. Medicaid data from all 50
states were used to identify prescriptions at the individual patient
level. As our definition of chronic AF required medical claims data
(from Medicare), as well as information on prescription medications
(from Medicaid), these sources were linked through a multistep
process shown in detail in Supplementary Figure S1 online. This
process permitted us to identify dually eligible (Medicare &
Medicaid) dialysis patients in 2004 and 2005.
We acquired patient demographic characteristics, comorbid
conditions, laboratory values before initiation of chronic dialysis,
date of dialysis initiation, and dialysis modality from the USRDS
from the Medical Evidence Form (the ‘CMS 2728’ form). This
detailed form is completed by providers for all patients when they
initiate dialysis, and is subsequently incorporated in the USRDS
database. All covariates used for the analysis were therefore
established before a determination of the chronic AF was under-
taken from the claims data.
Study cohort and rationale for analytical approach
We identified unique individuals above the age of 20 years who
survived 490 initial days on dialysis, who were Medicare eligible
for at least 90 days, who were simultaneously enrolled in Medicare
and Medicaid programs for at least 90 days during the 2-year
observation window, and who were alive (and still dually eligible) on
31 December 2005. We excluded individuals who initiated dialysis
before 1 January 1980, who were enrolled in the Veterans
Administration health-care system or any form of managed care
(and thus for whom we would not have complete records billing
claims or prescription records), and who received a transplant
before 1 January 2004. We censored patients if they lost eligibility for
either Medicare or Medicaid.
Determination of chronic AF
The ICD-9 code 427.31 was used to identify AF claims.14 To
determine the presence of nontransient, nonvalvular AF, we used an
algorithm adapted from Go et al.14,15,17 The cohort construction
strategy, relevant exclusions, and impact on sample size are depicted
in Figure 1. We began by eliminating individuals who had hyper-
thyroidism or thyrotoxicosis based on the presence of relevant ICD-9
and/or CPT (Common Procedural Technology) and/or HCPCS
(Healthcare Common Procedure Coding System) codes, or by a
prescription at any time for methimazole or propothiouracil.14,15
Drug exclusions were defined by matching name and therapeutic
class information from the Medicaid prescription drug files with
National Drug Codes from Multum Lexicon (Cerner Corporation,
Kansas City, KS). Next, we eliminated patients with evidence of
valvular heart disease (using ICD-9 codes). We then eliminated
individuals with incomplete data on the CMS 2728 dialysis intake
form. Finally, to minimize potential misclassification from perio-
perative sources of AF (for example, coronary artery bypass surgery),
claims (rather than individuals) were eliminated unless there was a
preexisting (430 days) AF claim. This resulted in the elimination
of individuals in whom AF claims were only proximally related
to cardiac surgery.14,15 A specific accounting of this exclusionary
strategy is listed in detail in Supplementary Table S2 online.
To classify individuals as having chronic AF, we initially required
a total of two (or more) AF claims, separated byX30 days, of which
no more than one was an inpatient claim.14,15 However, manual
inspection of the claims patterns of 4200 individuals with AF
claims revealed that a large number of outpatient AF claims
appeared immediately before and/or soon after an extended
hospitalization that contained an AF claim. To help rigorously
establish the presence of truly chronic AF, we formulated criteria for
an ‘episode-of-care’ window. Because we wanted to guard against
overattribution (that is, giving inappropriate credit to multiple AF
claims when they truly reflected only a single episode of care), we
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expunged all outpatient AF claims within 7 days of a subsequent AF
claim-containing admission, thus retaining only that inpatient
claim. Similarly, as outpatient follow-up care for AF could be closely
tied to a recent hospital admission for AF, we expunged all
outpatient AF claims within 30 days after an AF claim-containing
admission, retaining only the original inpatient claim. By establish-
ing the 7-day pre- and 30-day post-admission windows, additional
AF claims likely to be associated with a single episode of care were
eliminated, whereas a single claim associated with the hospitaliza-
tion was retained.
We performed several sensitivity analyses. First, we used a more
liberal approach that did not include the episode-of-care window14,15
to capture individuals with chronic AF who might have been missed
with our primary approach. Second, because dialysis patients have
increased contact with the health-care system, and therefore have
more opportunities to acquire AF claims than do other nondialysis-
requiring ambulatory patients, we amended the original algorithm
used by Go et al.14,15 by requiring a third AF claim (no more than
one of which could be an inpatient claim) in order to determine how
this more conservative approach would affect our results. Finally, to
compare our results with the larger dialysis population, we per-
formed one additional analysis in which the full Medicare population
(irrespective of Medicaid eligibility, and therefore more representa-
tive of the US dialysis population as a whole) was investigated, using
the two-claim approach with the episode-of-care window invoked
(that is, the identical approach used in the primary analysis for the
dually eligible patients). It is noteworthy that as only a subset of
individuals with Medicare have Medicaid, and because we relied on
Medicaid prescription records to eliminate people with presumptive
hyperthyroidism (an important cause of chronic AF), the definition
of chronic AF in the broader Medicare population could not use
information from prescription records.
Independent variables
A variety of covariates, as recorded on the CMS 2728 dialysis intake
form, were considered for analysis. The relationship of each
covariate to include with the model with the outcome was
considered a priori. Dichotomous variables were classified as being
present or absent at the time of dialysis initiation. Demographic
variables were age, sex, and race by ethnicity (four mutually
exclusive groups consisting of non-Hispanic Caucasian, non-
Hispanic African American, Hispanic, and Others). BMI was
classified into four categories: o20, 20–24.99, 25–29.99, and
X30 kg/m2. Risk behavior factors examined were smoking and
substance abuse (alcohol or illicit drugs), and functional status
markers were employment, inability to ambulate, and inability to
transfer. Major comorbidities were considered to be diabetes
(types 1 and 2 combined), HTN, congestive heart failure, CAD,
cerebrovascular disease, peripheral vascular disease, and cardiac
dysrhythmia. As the CMS 2728 form is structured such that diseases
such as diabetes or HTN may be considered as both a cause of ESRD
and/or a ‘freestanding’ comorbidity, for the purposes of the present
analysis, diabetes and HTN were considered a comorbidity if they
were listed as either the cause of ESRD or as a freestanding
comorbidity on the CMS 2728 form.27 This approach therefore
required a series of linear contrasts of the model parameters for
statistical inference (see below). Modality upon initiation of dialysis
was categorized as in-center hemodialysis or self-care dialysis (home
hemodialysis or peritoneal dialysis). To examine the association of
anemia, which has been identified as an important AF predictor in
the nondialysis population, we included baseline hemoglobin at
baseline, which was dichotomized at 11 g/dl. Serum albumin was not
analyzed, as B20% of individuals did not have this value recorded.
Statistical analyses
We generated descriptive statistics (means for continuous variables and
percentages for categorical variables) for the patients with and without
chronic AF. To explore the differences between two groups (that is,
those with and without chronic AF) through bivariate analyses, we
performed Pearson’s w2 tests for categorical measures and the two-
sample t-test for continuous measures. Raw percentages of individuals
who ever satisfied the definition of chronic AF (irrespective of length of
follow-up time) were generated for each of the approaches, and 95%
Wald CIs were generated. The number of individuals with chronic AF
on 31 December 2005 was ascertained, and multivariable logistic
regression was used to estimate adjusted prevalence odds ratios for
factors associated with chronic AF. Age was dichotomized at 60 years to
improve fit of the model. APORs for chronic AF were generated for
each covariate. Lack of fit for this model was evaluated using the
Hosmer–Lemeshow goodness-of-fit test.
We used a P-value of o0.01 to be the threshold for statistical
significance. This approach allowed us to reduce the likelihood of a
type 1 error with (presumably) minimal impact on the power to
detect significant finding given the large sample size. All statistical
analyses were performed with SAS 9.2 (Cary, NC).
Compliance and protection of human research participants
The research protocol was approved by the institutional review
board at the University of Kansas Medical Center (KUMC), and the
project was undertaken according to the Declaration of Helsinki
Principles. Data Use Agreements (DUA) between KUMC and the
USRDS and CMS permitted the data linking across the USRDS,
Medicare, and Medicaid files. In accordance with our DUA, social
security numbers and other identifying information were removed
from the linked files provided by CMS and the USRDS.
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